Massimo Cristofanilli Selected Research

Doxorubicin (Adriamycin)

12/2018	Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy.
10/2013	Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
3/2010	Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
2/2009	Nanotechnology for breast cancer therapy.
12/2008	Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
12/2005	The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
9/2005	Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
9/2005	Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
8/2005	Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
8/2005	Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Massimo Cristofanilli Research Topics

Disease

187	Breast Neoplasms (Breast Cancer) 03/2024 - 04/2002
160	Neoplasms (Cancer) 03/2024 - 10/2002
43	Neoplasm Metastasis (Metastasis) 04/2023 - 10/2002
40	Inflammatory Breast Neoplasms 01/2023 - 02/2004
35	Circulating Neoplastic Cells 01/2024 - 03/2005
19	Triple Negative Breast Neoplasms 05/2023 - 03/2008
14	Disease Progression 03/2023 - 04/2002
10	Pathologic Complete Response 10/2013 - 06/2005
9	Neutropenia 01/2021 - 05/2012
5	Carcinoma (Carcinomatosis) 01/2023 - 04/2003
5	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 01/2003
4	Febrile Neutropenia 01/2021 - 07/2015
4	Infections 01/2021 - 05/2012
4	Lung Neoplasms (Lung Cancer) 06/2019 - 08/2008
4	Anemia 09/2018 - 11/2014
3	Lobular Carcinoma 12/2022 - 01/2005
3	Carcinogenesis 12/2020 - 12/2014
3	Exanthema (Rash) 01/2020 - 11/2016
3	Fatigue 01/2020 - 07/2015
3	Pleural Effusion (Pleural Effusions) 10/2016 - 06/2010
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024 - 01/2020
2	Brain Neoplasms (Brain Tumor) 01/2023 - 09/2019
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2021 - 11/2017
2	Diarrhea 01/2020 - 11/2016
2	Noninfiltrating Intraductal Carcinoma (DCIS) 08/2019 - 10/2016
2	Thrombocytopenia (Thrombopenia) 09/2018 - 07/2015
2	Hypothyroidism 01/2017 - 06/2009
2	Leukopenia 01/2017 - 07/2015

Drug/Important Bio-Agent (IBA)

55	Hormones (Hormone)IBA 03/2024 - 01/2004
37	Biomarkers (Surrogate Marker)IBA 01/2024 - 12/2006
30	palbociclibIBA 03/2024 - 07/2015
29	Estrogen ReceptorsIBA 10/2023 - 02/2004
24	Circulating Tumor DNAIBA 01/2024 - 01/2013
23	ErbB Receptors (EGF Receptor)IBA 03/2024 - 06/2005
18	Proteins (Proteins, Gene)FDA Link 10/2022 - 02/2003
16	Fulvestrant (Faslodex)FDA Link 03/2024 - 07/2015
14	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 02/2004
12	human ERBB2 proteinIBA 01/2023 - 06/2005
12	AnthracyclinesIBA 01/2012 - 04/2002
11	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2018 - 01/2003
10	Cyclin-Dependent Kinase 4IBA 03/2024 - 01/2017
10	Cell-Free Nucleic AcidsIBA 11/2021 - 10/2016
9	Progesterone Receptors (Progesterone Receptor)IBA 01/2023 - 12/2006
9	DNA (Deoxyribonucleic Acid)IBA 12/2022 - 05/2016
9	Docetaxel (Taxotere)FDA Link 12/2018 - 04/2002
8	Trastuzumab (Herceptin)FDA Link 09/2018 - 04/2002
7	Messenger RNA (mRNA)IBA 01/2023 - 09/2005
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2013 - 07/2003
6	Cyclin-Dependent Kinases (cdk Proteins)IBA 03/2024 - 10/2006
6	Aromatase InhibitorsIBA 03/2024 - 01/2004
6	Estrogens (Estrogen)FDA Link 04/2013 - 07/2003
6	Taxoids (Taxanes)IBA 01/2012 - 05/2002
6	Fluorouracil (Carac)FDA LinkGeneric 03/2010 - 05/2002
5	Epidermal Growth Factor (EGF)IBA 03/2023 - 06/2010
5	Immune Checkpoint InhibitorsIBA 05/2022 - 01/2017
5	Chemokine ReceptorsIBA 01/2022 - 06/2007
5	AntibodiesIBA 01/2021 - 01/2003
4	Tumor Biomarkers (Tumor Markers)IBA 01/2024 - 10/2002
4	LigandsIBA 04/2023 - 07/2004
4	Epithelial Cell Adhesion MoleculeIBA 01/2022 - 06/2009
4	Monoclonal AntibodiesIBA 01/2021 - 02/2003
4	Phenobarbital (Luminal)FDA Link 11/2020 - 08/2005
4	Peptides (Polypeptides)IBA 01/2020 - 01/2003
4	taxaneIBA 09/2018 - 09/2003
4	Cadherins (E-Cadherin)IBA 04/2016 - 12/2006
4	Lapatinib (GW572016)FDA Link 01/2013 - 06/2010
4	Transcription Factors (Transcription Factor)IBA 11/2012 - 12/2005
3	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2019
3	ChemokinesIBA 01/2022 - 06/2007
3	Tamoxifen FDA LinkGeneric 01/2020 - 05/2005
3	AntigensIBA 01/2018 - 02/2007
3	MicroRNAs (MicroRNA)IBA 01/2018 - 07/2010
3	Anastrozole (Arimidex)FDA LinkGeneric 11/2016 - 03/2010
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 08/2010 - 02/2009
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 06/2010 - 01/2008
3	ParaffinIBA 05/2005 - 11/2003
2	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 05/2022
2	Phosphotransferases (Kinase)IBA 01/2022 - 01/2021
2	Letrozole (Femara)FDA LinkGeneric 01/2021 - 01/2020
2	CytokinesIBA 01/2021 - 08/2019
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2020 - 01/2020
2	Capecitabine (Xeloda)FDA Link 01/2020 - 06/2010
2	CyclinsIBA 10/2019 - 01/2019
2	exemestane (Aromasin)FDA Link 01/2019 - 01/2016
2	Antineoplastic Agents (Antineoplastics)IBA 12/2018 - 10/2013
2	EnzymesIBA 09/2018 - 09/2009
2	Thymidine KinaseIBA 01/2018 - 11/2016
2	Anaplastic Lymphoma KinaseIBA 01/2018 - 01/2013
2	Genetic Markers (Genetic Marker)IBA 06/2017 - 10/2014
2	Cell Surface ReceptorsIBA 11/2016 - 05/2005
2	AZD 8931IBA 11/2016 - 05/2014

Therapy/Procedure

121	Therapeutics 03/2024 - 04/2002
44	Drug Therapy (Chemotherapy) 03/2023 - 04/2002
19	Neoadjuvant Therapy 01/2024 - 04/2003
11	Radiotherapy 01/2018 - 02/2004
8	Precision Medicine 12/2022 - 11/2016
6	Immunotherapy 03/2024 - 01/2018
4	Drug Tapering 12/2020 - 05/2012
4	Segmental Mastectomy (Lumpectomy) 01/2018 - 09/2004
3	Mastectomy (Mammectomy) 10/2016 - 09/2004